Recognize
A SYGPeD™ interface configured for the target establishes the reference condition.
SYGPeD™ · RUO
Quantitatively measure candidate effects on a targeted interaction.
SYGPeD™ is SYG BIOTECH’s quantitative functional biosensing platform, primarily focused on immune-checkpoint R&D. It compares candidate effects at the level of the interaction under study.
Immune checkpoints · PD‑1/PD‑L1
A comparative readout that is immediately understandable.
A reference condition measures target engagement with the SYGPeD™ recognition interface. In the presence of a candidate, perturbation of that engagement produces a measurable signal change.
Functional readout: measurement of the candidate’s effect on the targeted interaction in the assay context.
Reference
Target → SYGPeD™ recognition interface
High signal
Same module · two comparable conditions
With candidate
Candidate perturbs target engagement
Lower signal
Measurement principle
Recognize → Translate → Quantify
The public site explains the assay at the level needed to understand its logic: a dedicated recognition interface engages the target, the biosensor translates that event into a measurable signal, and the readout is compared across conditions.
Translate
Target engagement is converted by the biosensor into a measurable signal.
Quantify
The signal is normalized and compared to measure candidate effect.
Experimental value
A proprietary biosensing architecture designed for comparison and confirmation.
SYGPeD™ converts a targeted interaction into a quantitative readout that can support screening and confirmation workflows.
Targeted interaction
The module is configured around a defined biological interaction and suitable controls.
Quantitative readout
Signal change supports condition comparison and candidate prioritization.
Experimental continuity
The same framework can support initial screening followed by dose-response confirmation.
Multi-target validation
An immune-checkpoint focus supported by an architecture already tested across multiple target families.
PD‑1/PD‑L1 is the reference immune-checkpoint module. Experimental validation on HER2, EPO and several cytokine models supports platform modularity. Performance remains specific to each module and protocol.
PD‑1 / PD‑L1
Comparative readout, screening and dose-response confirmation depending on configuration.
HER2
Module implemented experimentally.
EPO
Module implemented experimentally.
Cytokines
Several models used to evaluate architecture adaptability.
Workflow
Configure → Measure → Analyze
Configure
Define target, candidates, controls and assay conditions.
Measure
Read the luminescent signal with a system compatible with the module.
Analyze
Normalize, compare, prioritize and confirm by dose-response where appropriate.
* Indicative timing depends on module and protocol.
Outputs
Screening and quantitative confirmation.
Single-concentration screening
Compare a candidate series using defined controls and prioritize hits.
Dose-response
Confirm selected candidates and estimate IC₅₀ when supported by design and quality criteria.
Conceptual illustrations; demonstration charts are not experimental data unless explicitly stated.
Formats & new modules
An adaptable framework for different candidates and biological questions.
Biomolecules
Antibodies, VHHs, DARPins, peptides and other formats can be studied depending on the module.
Small molecules
Evaluation is framed according to the experimental configuration and appropriate controls.
New targets
Feasibility for a new module is defined with the partner before the study.
Evaluate SYGPeD™ on your project.
We can frame a pilot study around a target, controls and a clear experimental decision.